Table 5. Clinical characteristics of the GBM patients included in the series 1 (n=76) and their association to disease outcome.
| Clinical/genetic characteristics | Patient distribution | Overall survival | ||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||||
| Median (range) | p-value | Hazard Ratio (95% CI) | p-value | |||
| Age | >30 | 2 (2%) | 67 (2.7-67) | <.001 | ||
| 31-45 | 9 (12%) | 15 (8-21) | ||||
| 46-60 | 21 (28%) | 14 (2-63) | ||||
| 61-75 | 34 (45%) | 13 (2-83) | ||||
| >75 | 10 (13%) | 6 (2-11) | ||||
| Karnofsky Index # | >70 | 48 (64%) | 15 (2-83) | .004 | ||
| ≤70 | 27 (36%) | 10 (2-30) | ||||
| Type of Surgery | Complete resection | 24 (32%) | 15 (2-83) | .012 | ||
| Partial resection | 41 (54%) | 13 (2-67) | ||||
| No resection | 11 (14%) | 6 (2-21) | ||||
| Adjuvant chemotherapy# | Stupp | 43 (67%) | 18 (2-83) | <.001 | 3 (2-4) | <.001 |
| BCNU | 10 (16%) | 13 (5-67) | ||||
| No chemotherapy | 11 (17%) | 6 (2-11) | ||||
| Gene amplification profile | No gene AMP | 34 (45%) | 13 (2-67) | <.001 | ||
| Isolated EGFR AMP | 16 (21%) | 17 (9-83) | ||||
| Multiple AMP including EGFR | 12 (16%) | 13 (2-29) | ||||
| Isolated non-EGFR AMP | 9 (12%) | 6 (2-15) | ||||
| Multiple AMP without EGFR | 5 (6%) | 8 (2-9) | ||||
| No gene AMP+EGFR AMP | 62 (82%) | 14 (2-83) | <.001 | 6 (2-12) | <.001 | |
| AMP without EGFR | 14 (18%) | 6 (2-15) | ||||
CI: confidence interval; #: Data of Karnofsky index and adjuvant chemotherapy were only available in only 75 and 65 GBM patients respectively; Stupp: radiotherapy plus temozolamide; BCNU: carmustine; AMP: genetic amplification.